Today: 19 July 2026
Browse Category

NASDAQ:MRNA 24 January 2026 - 10 July 2026

For live price, interactive charts, financials and the latest market data, visit Google Finance.
US equities this week: AI chip slide grabs focus as rest of market holds up

US equities this week: AI chip slide grabs focus as rest of market holds up

U.S. stock markets stayed closed Saturday, so investors looked back on a mixed week. The S&P 500 ended down, but Friday’s internals pointed higher. Advancers led decliners in the S&P 500 by 1.8-1, with 35 stocks notching new highs and only five setting new lows. On the Nasdaq, 263 stocks hit highs while 169 hit lows. Overall U.S. trading volume ran to 30.1 billion shares, topping the 20-day average of 23.1 billion.
27 June 2026
·····
US futures edge lower ahead of Russell index reshuffle as chip stocks see selling

US stocks: After-hours chips slump overshadows gains ahead of jobs data

U.S. stocks finished Friday with the S&P 500 down 0.05% at 7,354.02, Nasdaq off 0.24% to 25,297.62, and the Dow lower by 0.09% at 51,876.11. The Russell 2000 added 0.1% Friday and booked a 1% gain for the week. Index losses looked modest under the surface.
27 June 2026
············
Moderna Rises After FDA Review Renews Optimism on mRNA Flu Shot

Moderna Rises After FDA Review Renews Optimism on mRNA Flu Shot

Moderna, Inc. shares jumped Tuesday after FDA staff reviewers said data on the company’s mFlusiva flu shot “may support effectiveness” in adults 65 and up. Moderna traded at $57.19, up about 9.7%. The stock hit an intraday high of $57.36 on nearly 6.8 million shares traded. SPDR S&P 500 ETF Trust slipped 0.4%, with Invesco QQQ Trust down 1.4%.
16 June 2026
·
Moderna Revenue Beat: Overseas Covid Shot Sales Jump, but $900 Million Charge Clouds the Turnaround

Moderna Revenue Beat: Overseas Covid Shot Sales Jump, but $900 Million Charge Clouds the Turnaround

Moderna Inc. topped first-quarter revenue forecasts Friday, with international Covid-19 vaccine sales outpacing what the U.S. market delivered—setting the biotech up for a stronger 2026 kickoff than many investors had penciled in. Revenue hit $389 million, a jump from $108 million the previous year, and of that, $311 million was generated outside the U.S.)
1 May 2026
·
1 2 3 4
Go toTop